May 1, 2012 (New Orleans, Louisiana) — A transdermal patch that delivers 8 mg of the dopamine-receptor agonist rotigotine (Neupro, UCB) in a once-daily, single application is the lowest effective dose ...
August 4, 2011 — A new study is the first long-term prospective trial of dopamine agonist therapy in restless legs syndrome (RLS). The study, funded by UCB BioSciences and Schwarz Pharma, ...
VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to report an update on its commercialization plan for its ...
A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...
VANCOUVER, BC / ACCESSWIRE / May 15, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has received government approval for to ...
A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the ...
Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback